Apellis Pharmaceuticals/$APLS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Ticker

$APLS
Primary listing

Industry

Biotechnology

Employees

708

APLS Metrics

BasicAdvanced
$2.4B
-
-$1.80
0.66
-

What the Analysts think about APLS

Analyst ratings (Buy, Hold, Sell) for Apellis Pharmaceuticals stock.

Bulls say / Bears say

Apellis Pharmaceuticals reported $781.4 million in full-year 2024 revenues, representing a 97% year-over-year growth, driven by strong sales of SYFOVRE® and EMPAVELI® (lifesciencereport.com).
The company announced a royalty purchase agreement with Sobi, providing up to $300 million in non-dilutive financing, which strengthens Apellis' balance sheet and supports future growth initiatives (globenewswire.com).
Positive Phase 3 study results for EMPAVELI® in treating C3G and primary IC-MPGN demonstrated sustained efficacy at one year, potentially expanding the drug's market and revenue streams (globenewswire.com).
Apellis Pharmaceuticals faced a setback when the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on pegcetacoplan for treating a rare blood disorder, leading to a share price decline (investing.com).
The company discontinued the open-label extension phase of its MERIDIAN trial for ALS treatment based on external advisors' feedback, indicating challenges in expanding its drug pipeline (biopharmadive.com).
Apellis' stock experienced a significant decline, with shares plunging 4.18% amid regulatory setbacks, reflecting investor concerns over the company's ability to navigate approval processes (ainvest.com).
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.

APLS Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

APLS Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $APLS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs